Running title: CD44 cleavage increases CREB phosphorylation.
shown to be unique and identical to those reported in Schweppe et al., 2008 (21) . In brief, 15 STR loci were tested by using the Applied Biosystems AmpF L STR Identifiler kit (ABI no.
4322288, Forest City, CA); DNA profiles were compared manually to the American Type
Culture Collection database and to the DNA profiles reported by Schweppe et al. 2008 (21) .
Human primary culture of thyroid cells (P5) were obtained from F. Curcio (University Udine, Italy) in 2003 and passaged in our laboratory, as described (22) , for fewer than 2 months after resuscitation. They were tested in 2010 by proliferation rate and expression of thyroid differentiation markers (TG, TPO and TSHR). Nthy-ori 3-1 (hereafter referred to as NTHY), a human thyroid follicular epithelial cell line immortalized by the SV40 large T gene, was obtained from European Collection of Cell Cultures (ECACC) (Wiltshire, UK) in 2010. They were tested by ECACC for identity verification by DNA profiling of short tandem repeat sequences and were passaged in our laboratory for fewer than 3 months after resuscitation. PC Cl 3 (hereafter referred to "PC") is a differentiated thyroid follicular cell line derived from 18-month-old Fischer rats in our laboratory in 1987 (23) . They were kept in culture for fewer than 3 months after resuscitation and tested in 2010 by proliferation rate, dependence on six hormones for growth and expression of thyroid differentiation markers (TG, TPO and TSHR).
HEK293T cells were purchased in 2006 from the American Type Culture Collection and tested by ATCC for identity by DNA profiling of short tandem repeat sequences. HEK293T
were passaged in our laboratory for fewer than 3 months after resuscitation. The PC ICD and 5 BCPAP ICD cell lines were obtained by a stable transfection with the CD44-ICD construct by using the Fugene HD reagent from Roche Diagnostics (Mannheim, Germany). A pool of several cell clones was isolated by G418 selection. Transient transfections were carried out with the Fugene HD reagent. All these cell lines were grown in standard conditions as detailed in Supplemental Methods.
Plasmids. - The RET/PTC constructs used in this study were cloned in pBABE or pcDNA3(Myc-His) (Invitrogen, Groningen, The Netherlands) and described elsewhere (14) .
RET/PTC3(K-) is a kinase-dead mutant, carrying the substitution of the catalytic lysine (residue 758 in full-length RET) with a methionine. In RET/PTC3(4YF) mutant the 4 major autophosphorylation sites (Y826, Y1015, Y1029, Y1062 in full-length RET) are mutated to phenylalanine; Y1062 has been added back in RET/PTC3(3YF). These mutants were generated by site-directed mutagenesis using the QuikChange mutagenesis kit (Stratagene, La Jolla, CA, USA). BRAFV600E and HRAS(V12) plasmids are described elsewhere (14) . The full-length rat CD44 was cloned into pDEST47 vector and tagged at the C-ter with GFP (17);
CD44-ICD was cloned in pDEST47 (GFP-tagged), pDEST40 (V5-tagged), and pCDNA 3.1 (myc-tagged) (17) .
Antibodies, compounds and proteins. -The antibody against the cytosolic portion of CD44 (CD44cyto) and anti-RET are described elsewhere (14, 17) . A list of commercial antibodies, compounds and recombinant proteins used in this study is provided in Supplemental Methods. passages through a 26-gauge needle mounted in a 1 ml syringe. Nuclei were recovered by centrifugation at 3,000 x g for 10 m (Supplemental Methods).
Pull down assay. -The GST-CD44-ICD vector codes for a chimeric protein with CD44-ICD fused to the glutathione S-transferase (GST). It was generated by the Invitrogen Gateway technique using as donor the pDEST47-CD44-ICD vector and as recipient the pDEST15 vector. GST-CD44-ICD was purified from pDEST15-CD44-ICD transformed bacterial lysates using glutathione-Sepharose beads. Recombinant proteins containing the different domains of CREB fused to GST are described elsewhere (24) . Pull down assays were performed by standard procedures (Supplemental Methods).
Reporter assay. -All the Firefly luciferase reporters were kindly provided by J.S. Gutkind 8 phosphorylated by the catalytic subunit of PKA in a buffer containing 1 mM ATP, 10 mM MgCl 2 , 50 mM KCl, 10 mM Hepes and 10% glycerol for 1h at 30°C. Phosphorylated CREB was incubated in a phosphatase buffer (40 mM Tris HCl, 34 mM MgCl 2 , 4 mM EDTA, 2 mM DTT, 0.05 mg/ml BSA) for 1 h at 37°C with 10 μU of PP2A catalytic subunit. GST-CD44-ICD, or the GST backbone alone, were added to the samples. The reaction was terminated by adding SDS gel loading dye and samples were run on 10% SDS-polyacrylamide gel.
Phospho-CREB signal was detected with anti-phospho(Ser/Thr) PKA substrate antibody and the amount of CREB in each reaction was estimated with anti-HIS antibody.
Statistical analysis.-The two-tailed unpaired Student's t test (normal distributions and equal variances) was used for statistical analysis. Differences were significant when P < 0.05.
Statistical analysis was performed using the Graph Pad InStat software program, version 3.06.3 (San Diego, CA).
Results

CD44-ICD stimulates CRE-mediated transcription.
-We analyzed the capability of a GFP-tagged CD44-ICD construct to trans-activate a panel of promoter elements, including AP-1 (activating protein-1), SRF (serum response factor), TCF (ternary complex factor), Gli (Glioma-associated oncogene homolog), NFkB (nuclear factor kappa B) and CRE (cAMPresponsive element) reporters (25) (26) (27) (28) . CD44-ICD strongly (about 10 fold, P < 0.01) activated the CRE reporter in HEK293T cells, but not the other promoters (Fig. 1A ). This was a specific feature of the cleaved CD44-ICD, because full length GFP-tagged CD44 did not significantly (P > 0.05) stimulate the CRE reporter (Fig. 1B) . Cyclin D1 (CCND1) is a prototypic CREB transcriptional target, containing a CRE element upstream of the mRNA start site (at -58 bp) (25, 31) . We studied the effect of CD44-ICD on a CCND1-luciferase reporter. HEK293T cells were kept without serum for 24 h after the transfection to reduce the growth factor-dependent CCND1 promoter activity. CD44-ICD stimulated (approximately 12 fold, P < 0.01) the CCND1 promoter ( The co-activator CBP/p300 binds to active S133-phosphorylated CREB and triggers CREB-mediated gene transcription (32) . Previous data demonstrated that CD44-ICD stimulates p300-mediated transactivation (33) . Thus, we co-transfected CD44-ICD with p300 or a p300-dominant negative construct (LYRR) (34) . CD44-ICD upregulated (about 3 fold) endogenous CCND1 expression; the p300-dominant negative mutant blocked CD44-ICDinduced CCND1 expression, whereas wt p300 slightly increased it (Fig. 1D ).
Phosphorylated CREB is recruited to CRE sites in DNA (35) . We performed a chromatin immunoprecipitation (ChIP) to measure CREB binding to the CRE element of the CCND1 promoter. CD44-ICD expression increased the binding of CREB to the CCND1 promoter by about 5 fold (Fig. 1E ).
Taken together, these results demonstrate that CD44-ICD stimulates CREB recruitment to CCND1 promoter and CREB/p300-mediated transcription of CCND1. and ATF-1 (38 kDa). Expression of CD44-ICD induced a robust increase of pS133 CREB as well as of phosphorylated ATF-1 ( Fig. 2A, left) . Activated pS133 CREB binds p300 and this results in a transcriptionally active complex. Thus, we analyzed CREB-p300 interaction by immunoprecipitating CREB from nuclear extracts of HEK293T cells co-transfected with CD44-ICD and p300, and staining the immunoblot with p300 antibody. CD44-ICD, as well as FSK treatment, increased (about 5 fold) the CREB-p300 interaction ( Fig. 2A, right ).
These results demonstrate that CD44-ICD expression increases levels of S133-phosphorylated CREB and its binding to p300.
CD44-ICD forms a protein complex with CREB. -We transfected HEK293T cells with V5-tagged CD44-ICD and stained anti-CREB immunoprecipitates with V5 antibody. CD44-ICD formed a protein complex with CREB (Fig. 2B) . To verify if the interaction between CREB and CD44-ICD was direct or mediated by other proteins, we performed a pull-down assay using recombinant CREB and GST-CD44-ICD proteins. Figure 2C shows that CREB and CD44-ICD readily interacted in vitro.
We used different domains of CREB expressed as recombinant proteins fused to GST (24) to pull-down myc-tagged CD44-ICD expressed in HEK293T cells. As shown in Figure   on The fact that CD44-ICD binds to a CREB domain different to that binding to p300 (KID domain) (29) is consistent with the possibility that a complex of three proteins, CREB, p300 and CD44-ICD is formed.
CD44-ICD reduces the rate of CREB de-phosphorylation. - Various serine/threonine kinases, i.e. PKA, RSK and MSK, are able to phosphorylate CREB on S133 and to stimulate CREB binding to DNA (29, 35, 36) . We evaluated the effects of the blockage of these Fig. S1 ).
These results prompted us to hypothesize that, in the presence of CD44-ICD, the increase of CREB phosphorylation levels occurs due to a reduced rate of CREB dephosphorylation rather than to activation of a specific CREB kinase. To evaluate this possibility, we stimulated serum-starved HEK293T cells for 40 min with the cAMP-analog N6-benzoyl-cAMP to induce S133 CREB phosphorylation, and then measured CREB binding to CD44-ICD. GST-CD44-ICD pulled-down a larger amount of CREB upon induction of CREB phosphorylation (Fig. 3A) , indicating that CD44-ICD, although able to bind dephosphorylated CREB, binds preferentially to pS133 CREB.
12
Then, we induced CREB phosphorylation with N6-benzoyl-cAMP in the presence or not of GFP-tagged CD44-ICD and chased pS133 CREB de-phosphorylation by immunoblot. Figure 3B shows that the pS133 CREB half-life was increased by CD44-ICD; CREB pS133 levels did not decrease up to 12 h in cells expressing CD44-ICD, while the half-life of pS133 CREB was about 8 h in mock-transfected cells (Fig. 3B ).
Finally, we performed an in vitro CREB de-phosphorylation assay. Recombinant HIStagged CREB was phosphorylated in vitro by PKA and then incubated with PP2A phosphatase in the presence or the absence of GST-CD44-ICD. As shown in Fig. 3C , GST-CD44-ICD, but not the GST backbone, protected phosphoCREB from PP2A-mediated dephosphorylation.
These findings demonstrate that CD44-ICD reduces the rate of CREB dephosphorylation on S133. informations, Fig. S3D ), which further supports the concept that the ERK pathway plays an important role in CD44 cleavage. Accordingly, also human thyroid carcinoma cell lines featuring mutant RAS alleles upregulated both CD44 and CD44-ICD with respect to nontransformed thyrocytes (Supplemental informations, Fig. S5 ).
Expression of CD44-ICD
These findings demonstrate that RET/PTC and BRAF signaling to ERK stimulates CD44 processing.
CD44-ICD sustains CREB phosphorylation and CCND1 expression in thyroid cancer
cells. -In BCPAP and TPC1 thyroid cancer cells, CD44 silencing by shCD44, but not the empty vector, attenuated CREB phosphorylation on S133 (Fig. 4A) . In shCD44-transfected cells, CREB phosphorylation was rescued by the transfection of a V5-tagged rat CD44-ICD mRNA that is shCD44-resistant because it has several mismatches with human shCD44 (Fig.   4A ). BB94 and DAPT, able to block CD44 cleavage, reduced CREB pS133 (Fig. 4B) . Downregulation of either CREB or CD44 by siRNA, but not a scrambled control, reduced (about 2 fold) the expression of CCND1 in BCPAP and TPC-1 cell lines (Fig. 4C ).
These findings demonstrate that CD44-ICD sustains CREB-dependent CCND1 expression in thyroid cancer cells.
CD44-ICD sustains proliferation of thyroid cells. -We silenced CD44 by transiently
transfecting BCPAP and TPC-1 cells with a human shCD44 plasmid. To exclude off-target effects, cells were co-transfected with the shCD44-resistant rat CD44-ICD construct. CD44 silencing reduced BrdU incorporation (P < 0.05) and this effect was rescued by adoptive expression of rat CD44-ICD (P < 0.05) (Fig. 5A ). CD44-ICD was not able to rescue the reduction of BrdU incorporation mediated by CREB silencing (P >0.05), that is consistent with CREB acting downstream CD44-ICD (Fig. 5A) . We treated BCPAP cells with the Ȗ-secretase inhibitor COMP X and, to rescue the effect, we transfected CD44-ICD or the empty vector. As shown in Figure 5B , COMP X inhibited DNA synthesis in BCPAP, and CD44-ICD was able to revert this effect. We stably expressed CD44-ICD in BCPAP and selected one mass population by G418 treatment. While treatment with COMP X reduced the growth rate of parental (P < 0.01) (Fig. 5C, left) , it did not change significantly (P > 0.05) the proliferation of BCPAP-ICD cells (Fig. 5C, right) .
Non transformed thyroid PC cells require a mixture of 6 hormones (6H), including TSH, for proliferation (23) . In hormone-starved PC cells, transiently transfected CD44-ICD stimulated CRE-mediated transcription (about 9 fold) ( 
Discussion
Here we report a novel functional link between CD44 and the CREB transcription factor.
CREB is involved in neoplastic transformation and, being activated via PKA by cAMP, is also involved in the growth of normal thyroid follicular cells (38) (39) (40) (41) -11-3320v2 CD44-ICD binds CREB and increases pS133 CREB levels. CD44-ICD stimulated CREBmediated gene transcription and recruitment of CREB to CCND1 gene promoter. We noted that CD44-ICD preferentially binds to phosphorylated CREB and that CD44-ICD expression attenuates the rate of CREB dephosphorylation, thus suggesting that interaction with CD44-ICD impairs CREB de-phosphorylation on S133. Accordingly, CD44-ICD protected pCREB from PP2A-mediated dephosphorylation in vitro.
Thyroid carcinoma overexpresses CD44 and such overexpression is associated to the oncogenic conversion of the ERK signaling pathway (18, 19) . Moreover, as in other cell types (42) , CD44 was expressed in prospectively identified thyroid cancer stem cells that induce tumors when injected orthotopically into mouse thyroid (43) . Thus, it is feasible that CD44 plays a role in thyroid cancer as well as in thyroid cancer stem cells.
Oncogenic RET point mutants induce CD44 cleavage (17) . Here, we show that CD44- Our findings support a model whereby CD44 cleavage acts as an amplifier of oncogenes signaling to CREB (Fig. 7) . According to this model, RET/PTC and BRAF promote CREB phosphorylation via ERK-mediated activation of CREB kinases and stabilize pS133-CREB through CD44-ICD. In turn, the CD44-ICD/CREB axis stimulates CCND1 transcription and thyroid cell proliferation. Should these results be validated in vivo, they may prompt the possibility of pharmacological manipulation of the pathway. 
